Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
The landscape of potential new gene therapies for Duchenne muscular dystrophy (DMD) is rapidly evolving, offering renewed hope for patients and families affected by...
The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control
The duchenne muscular dystrophy treatment cost has become one of the most controversial and morally troubling issues in modern medicine. From duchenne therapy cost...
The Accountability Crisis in Duchenne Muscular Dystrophy (DMD) Associations: Why Donations Must Lead to Measurable Outcomes
Where do DMD associations spend the donations they receive, and how much of it truly supports scientific research and clinical trials? Are donations being...
The Systemic Failure of DMD Associations: Why Duchenne Patients Are Still Waiting
Duchenne muscular dystrophy (DMD) is not a newly discovered condition, nor is it an unsolvable one. Scientific progress over the past two decades has...
NSAA Alone Is Not Enough: Why Creatine Kinase (CK), AST, ALT, and Dystrophin Levels Should Be Disclosed
So why do many DMD clinical trials avoid clearly reporting these key biomarkers? This article examines why CK, AST, ALT, and dystrophin data matter—and...